Did not become law. It stopped in the Senate on April 10, 2024. The 2024 session has ended.
2024 Regular Session
Senate Bill 241
AN ACT CONCERNING THE OFFICE OF HEALTH STRATEGY'S RECOMMENDATIONS REGARDING 340B PROGRAM TRANSPARENCY.
What it does
The synopsis the General Assembly published with the bill.
To require entities authorized to participate in the federal 340B Drug Pricing Program to report to the Health Systems Planning Unit of the Office of Health Strategy certain information regarding the program, including (1) aggregated acquisition costs, (2) aggregated payment information, (3) the number of claims for prescription drugs under the program, and (4) if the entity is a hospital, the national drug code number for the fifty most frequently dispensed prescription drugs by the hospital under the program.
Sponsors
Who carried the bill in each chamber, and who signed on. Each name leads to the member's page.
In the Senate
Sponsor
Its course
February 22 to April 10, 2024, on one scale. In the top row each mark is a day something happened; taller marks are busier days.
Each committee stop sits inside its chamber.
Every action9 actions on 6 days
In the SenateFeb 22 to Apr 10 · stopped48 days
Public Health CommitteeFeb 22 to Mar 2229 days
Text
Each version as the General Assembly printed it.
l9n doesn't hold this bill's text yet.
What happened
In l9n's words, one line for each step. Every action as the General Assembly published it is below.
In the Senate Feb 22 – Mar 22
- Feb 22Introduced and sent to Public Health Committee
- Feb 26Heard in Public Health Committee
- Mar 22Public Health Committee recommended a substitute for it
All 9 actions, as published
- Feb 22REF. TO JOINT COMM. ONBoth houses
- Feb 26PUBLIC HEARINGBoth houses
- Mar 22Joint Favorable SubstituteBoth houses
- Mar 25FILED WITH LCOBoth houses
- Apr 4REFERRED TO OLR, OFABoth houses
- Apr 10RPTD. OUT OF LCOBoth houses
- Apr 10FAV. RPT., TAB. FOR CAL., SEN.Senate
- Apr 10SENATE CALENDAR NUMBERSenate
- Apr 10FILE NO.Both houses